Company | JPMorgan Chase & Co. | Earnings Date | July 15, 2026 |
Ticker | JPM | Reporting Period | Q2 2026 |
Sector | Large-Cap U.S. Banks | Prepared Date | July 13, 2026 |
Sector ETF | KBE (SPDR S&P Bank ETF) | Last Close | $334.53 (July 13, 2026) |
Key Takeaway: The setup favors another beat — consensus is a manageable bar after only modest upward revision post-Q1, and JPM enters Q2 with markets and IB tracking in line to slightly ahead of estimates; the single biggest swing factor is whether the record-level trading volumes of Q1 can sustain into Q2 or mean-revert sharply.
JPMorgan heads into Q2 2026 earnings with consensus expecting diluted operating EPS of ~$5.56 and revenue of ~$50.9B — a bar that looks achievable but not easy given the exceptionally high Q1 2026 comp ($5.94 EPS, $49.8B revenue). Management held full-year NII ex-Markets guidance at ~$95B and expense guidance at ~$105B on the Q1 call (subsequently nudged to ~$106B at the Bernstein conference in late May, citing higher comp tied to strong fees and trading volumes), signaling confidence in the underlying earnings engine without over-promising on the volatile markets line. Estimate revisions have been modestly positive since Q1 earnings — the April 21 consensus for Q2 EPS stood at ~$5.41 vs. the current ~$5.56, a ~2.8% upward drift — suggesting the Street has partially priced in continued strength but has not fully extrapolated Q1's record markets performance. The stock has rallied ~7% from the April 14 earnings close of $311 to ~$335 today, outperforming the KBE (+8.6%) and broadly in line with the SPY (+7.8%), and now trades at roughly 14–15x forward earnings — a premium to historical norms that leaves limited room for a miss. The key wildcard is the sustainability of Markets revenue: FICC came in at $7.1B in Q1 (a record), and consensus for Q2 is ~$6.2B — a meaningful step-down that management has not explicitly guided against, but which peers (BAC, WFC, C) have broadly corroborated with constructive commentary on capital markets activity through mid-Q2.
Key Takeaway: Consensus is a moderate bar — the revenue and EPS estimates embed a meaningful step-down from Q1’s record quarter, but NII ex-Markets is the more predictable anchor while Markets revenue is the bigger swing factor. A beat on credit quality (card NCO rate) could be the positive surprise.
KPI | Q1 2026 Actual | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Est. | YoY Change | Guidance | Cons. vs. Guidance |
Total Revenue, Net of Interest Expense | $49.8B | $44.9B | $50.9B | +13.4% | FY ~$198B (implied) | In line |
NII ex-Markets (FTE) | $23.3B | $22.8B | $23.7B | +4.1% | FY ~$95B | +0.7% above run-rate |
Investment Banking Fees | $2.86B | $2.50B | $2.85B | +14.0% | Pipelines healthy; Middle East risk flagged | N/A (no explicit IB guidance) |
FICC Markets Revenue | $7.1B | $5.7B | $6.2B | +9.1% | No explicit quarterly guidance | N/A |
Equities Markets Revenue | $4.5B | $3.2B | $4.0B | +23.2% | No explicit quarterly guidance | N/A |
EPS — Diluted Operating | $5.94 | $4.96 | $5.56 | +12.1% | No explicit EPS guidance | N/A |
ROTCE | 22.4% | 21.1% | 22.4% | +130 bps | FY ~21.0% (implied) | Slightly above FY run-rate |
Card Net Charge-Off Rate | 3.47% | 3.40% | 3.50% | +10 bps | FY ~3.4% | +10 bps above guidance midpoint |
CET1 Ratio (Fully Phased-In) | 14.1% | 15.1% | 14.2% | -90 bps | Managed above regulatory minimums; SCB 2.5% | N/A (no explicit target) |
Total Noninterest Expenses | $26.9B | $23.8B | $26.5B | +11.4% | FY ~$106B (updated May 2026) | Slightly below FY run-rate |
Provision for Credit Losses | $2.5B | $2.8B | $3.1B | +10.7% | No explicit quarterly guidance | N/A |
Sources: Visible Alpha Consensus and Actuals Data; JPM Q1 2026 Earnings Call (April 14, 2026); Bernstein Strategic Decisions Conference (May 2026).
Key Takeaway: Management’s tone has shifted modestly more cautious on the consumer since Q1 earnings — flagging an emerging subset of customers where wage growth is no longer keeping pace with inflation — while remaining constructive on capital markets and NII. The expense guide nudge to ~$106B is a minor negative but reflects revenue strength, not cost creep.
Topic | Q1 2026 Earnings Call Guidance / Tone (April 14, 2026) | Revised / Updated Guidance (Post-Q1) | Direction |
NII ex-Markets (FY 2026) | ~$95B; unchanged despite rate path shift; EAR of $1.8B had minimal full-year impact | Unchanged at ~$95B as of latest commentary | → Unchanged |
Total NII (FY 2026) | ~$103B; Markets NII revised down to ~$8B due to rates, offset in NIR | Unchanged | → Unchanged |
Adjusted Expenses (FY 2026) | ~$105B; described as an “outcome of business results,” not a promise; upside risk if volumes stay elevated | Nudged to ~$106B at Bernstein conference (May 2026), citing higher comp tied to stronger fees and trading volumes | ↑ Slight increase (revenue-driven) |
Card Net Charge-Off Rate (FY 2026) | ~3.4%; tracking at low end of guided range; consumer resilient | Tracking at low end of range as of June 2026; management flagging emerging (small) subset of consumers where wage growth no longer keeping pace with inflation | → Unchanged but tone slightly more watchful |
Card Loan Growth (FY 2026) | ~6% or slightly more; unchanged from Company Update | Unchanged | → Unchanged |
Consumer Deposit Growth | Low-to-mid single digits; Q1 up 2% YoY/QoQ aided by tax refunds | Deposit growth inflection now expected in H2 2026 (pushed from H2 2025); lower personal savings rates and equity market flows cited | ↓ Timing pushed out |
Investment Banking / Pipelines | Pipelines “resilient, maybe surprisingly resilient”; Middle East risk flagged for deal timing; Q1 IB fees +28% YoY partly from accelerated M&A closures | Markets and IB revenues tracking in line to slightly ahead of estimates through mid-Q2 per management commentary | ↑ Constructive |
Capital Return | Patient deployment; Apple Card integration ongoing; buybacks secondary to organic growth | Post-CCAR (June 24, 2026): $50B buyback authorized (effective July 1); quarterly dividend raised 10% to $1.65/share (pending board approval) | ↑ Significantly more aggressive |
Consumer Macro Tone | Consumer resilient; credit quality better than expected; real wages under pressure in April 2026 for first time in a while | Watchful but not alarmed; cash buffers normalizing; labor demand softening for a small but growing subset of customers | ↓ Slightly more cautious |
Key Takeaway: Estimate revisions have been modestly positive since Q1 earnings, with Q2 2026 Operating EPS consensus rising ~2.8% from $5.41 (April 21 snapshot) to $5.56 currently — suggesting the Street has partially but not fully priced in continued markets strength. The NII ex-Markets estimate is tracking slightly above the implied quarterly run-rate of the $95B full-year guide, which is a mild positive.
KPI | Guidance / Management View | Consensus at Q1 Earnings (Apr 21, 2026) | Current Consensus (Jul 13, 2026) | Revision Direction | Gap vs. Guidance |
Operating EPS (Q2 2026) | No explicit quarterly EPS guidance | $5.41 | $5.56 | +2.8% ↑ | N/A |
Total Revenue (Q2 2026) | FY ~$198B implied; no Q2 explicit guide | $48.3B | $50.9B | +5.4% ↑ | In line with FY run-rate |
NII ex-Markets (Q2 2026) | FY ~$95B (~$23.75B/quarter implied) | $23.6B | $23.7B | +0.5% ↑ | +0.7% above implied quarterly run-rate |
IB Fees (Q2 2026) | Pipelines healthy; no explicit quarterly guide | $2.81B | $2.85B | +1.4% ↑ | N/A |
Total Expenses (Q2 2026) | FY ~$106B (~$26.5B/quarter implied) | $26.2B | $26.5B | +1.2% ↑ (slight creep) | In line with updated FY guide |
Sources: Visible Alpha Consensus and Actuals Data (April 21, 2026 as-of snapshot and current); JPM Q1 2026 Earnings Call; Bernstein Strategic Decisions Conference (May 2026).
Key Takeaway: JPM has rallied ~7.5% since Q1 earnings (April 14 close: $311.12 → July 13 close: $334.53), broadly in line with the SPY (+7.9%) and slightly lagging the KBE (+8.6%), suggesting the stock has not dramatically re-rated on a relative basis despite the exceptional Q1 beat — the premium multiple (~14–15x forward P/E) leaves limited margin for error heading into Q2.
Metric | JPM | KBE | SPY |
Close at Q1 Earnings (Apr 14, 2026) | $311.12 | $63.35 | $694.46 |
Close on July 13, 2026 | $334.53 | $68.82 | $749.17 |
Return Since Q1 Earnings | +7.5% | +8.6% | +7.9% |
52-Week Range (approx.) | ~$295–$340 | N/A | N/A |
Post-CCAR Rally (Jun 24 close) | $333.45 (+7.2% from Apr 14) | $67.49 | $733.24 |
Trough Since Q1 Earnings | $295.70 (May 19, 2026) | $61.68 (May 15) | $733.73 (May 19) |
Note: JPM sold off from ~$315 to ~$296 between late April and mid-May 2026 (a ~6% drawdown), likely reflecting broader macro concerns and the stock’s premium valuation. The stock recovered sharply in June, aided by the CCAR results (June 24) which triggered the $50B buyback authorization and 10% dividend hike announcement. The stock is now trading near its post-Q1 highs, entering Q2 earnings with a full valuation. Source: Stock Price Data.
Date | JPM (Indexed) | KBE (Indexed) | SPY (Indexed) |
Apr 14, 2026 (Base = 100) | 100.0 | 100.0 | 100.0 |
Apr 30, 2026 | 100.7 | 101.3 | 103.5 |
May 15, 2026 | 95.7 | 97.4 | 106.5 |
May 29, 2026 | 96.2 | 100.2 | 108.9 |
Jun 12, 2026 | 103.1 | 105.6 | 106.8 |
Jun 24, 2026 (CCAR) | 107.2 | 106.5 | 105.6 |
Jul 7, 2026 | 109.0 | 108.5 | 107.7 |
Jul 13, 2026 (Latest) | 107.5 | 108.6 | 107.9 |
Source: Stock Price Data. Indexed to 100 at April 14, 2026 close. Note: JPM underperformed the KBE and SPY through mid-May as the stock gave back some of its pre-earnings rally, then recovered sharply in June on CCAR-driven capital return announcements.
Key Takeaway: The most significant post-Q1 development is the CCAR-driven $50B buyback authorization and 10% dividend hike — a major capital return signal that reinforces the fortress balance sheet narrative. The Basel III endgame and GSIB surcharge proposals remain a medium-term overhang but are not expected to affect Q2 results.
Key Takeaway: Peer commentary from BAC, WFC, C, and GS across the Bernstein and Morgan Stanley U.S. Financials conferences (May–June 2026) is broadly constructive for JPM’s Q2 setup: NII is tracking at or above guidance across the group, IB pipelines are described as full and active, consumer credit quality remains solid, and capital markets activity is strong. The one consistent caution is macro uncertainty (Middle East, tariff drag) that could affect deal timing.
Read-Through Relevance: HIGH. BAC is JPM’s closest large-cap peer across consumer banking, NII sensitivity, and capital markets.
Read-Through Relevance: MEDIUM-HIGH. WFC is a key read-through on consumer banking, NII, and credit quality, though less relevant on capital markets.
Read-Through Relevance: MEDIUM. Citi is most relevant as a read-through on institutional/wholesale banking, capital markets, and global macro sentiment.
Read-Through Relevance: HIGH for capital markets (FICC, equities, IB). GS is the most direct read-through for JPM’s CIB performance.
Peer | NII / Deposits | Consumer Credit | IB / Capital Markets | Macro Tone | Overall JPM Read-Through |
BAC | ↑ Positive (guidance raised to 6–8%) | ↑ Positive (credit quality “great”) | ↑ Positive (pipelines full, IB “very strong”) | Constructive; GDP ~2.2% | POSITIVE |
WFC | → Neutral/Positive (stable NII) | → Neutral (stable, no deterioration) | → Neutral (less capital markets exposure) | Stable; efficiency focus | NEUTRAL/POSITIVE |
C | → Neutral (transformation ongoing) | → Neutral (no material issues) | ↑ Positive (institutional client activity solid) | Cautious on geopolitics | NEUTRAL/POSITIVE |
GS | N/A (no NII focus) | N/A | ↑ Positive (strong markets, M&A, underwriting) | Constructive; capital return confidence | POSITIVE |
Sources: BAC Bernstein Strategic Decisions Conference (May 27, 2026); BAC Morgan Stanley U.S. Financials Conference (June 9, 2026); WFC Morgan Stanley U.S. Financials Conference (June 9, 2026); WFC Bernstein Strategic Decisions Conference (May 27, 2026); C Investor Day (May 7, 2026); C Morgan Stanley U.S. Financials Conference (June 9, 2026); GS Bernstein Strategic Decisions Conference (May 28, 2026); GS CCAR Statement (June 24, 2026); MS CCAR Statement (June 24, 2026).
Key Takeaway: All insider transactions since Q1 earnings are sales, and all are under pre-established 10b5-1 trading plans — indicating these are scheduled, non-discretionary dispositions rather than signals of negative conviction. The most notable is CEO Jamie Dimon’s sale of 130,488 shares on April 15, 2026, consistent with his previously disclosed plan. No open-market purchases by insiders have been recorded in the period.
Date | Insider | Role | Transaction | Shares | 10b5-1 Plan? | Shares Owned After |
Apr 15, 2026 | James Dimon | Chairman & CEO | Sale | 130,488 | Yes | 1,680,625 |
Apr 15, 2026 | Ashley Bacon | Chief Risk Officer | Sale | 7,558 | Yes | 252,855 |
Apr 15, 2026 | Jeremy Barnum | Chief Financial Officer | Sale | 5,611 | Yes | 35,460 |
Apr 15, 2026 | Lori A. Beer | Chief Information Officer | Sale | 3,166 | Yes | 69,948 |
Apr 15, 2026 | Marianne Lake | CEO, CCB | Sale (via GRATs) | 6,427 | Yes | 130,872 |
Apr 15, 2026 | Douglas B. Petno | Co-CEO, CIB | Sale | 5,660 | Yes | 381,807 |
Apr 15, 2026 | Jennifer Piepszak | Chief Operating Officer | Sale | 9,136 | Yes | 90,001 |
May 5, 2026 | Ashley Bacon | Chief Risk Officer | Sale | 4,070 | Yes | 248,785 |
May 5, 2026 | Jeremy Barnum | Chief Financial Officer | Sale | 3,022 | Yes | 32,438 |
May 5, 2026 | Jennifer Piepszak | Chief Operating Officer | Sale | 4,919 | Yes | 85,082 |
May 15, 2026 | Lori A. Beer | Chief Information Officer | Sale | 3,165 | Yes | 66,783 |
May 15, 2026 | Marianne Lake | CEO, CCB | Sale (via GRATs) | 6,427 | Yes | 76,402 |
May 15, 2026 | Douglas B. Petno | Co-CEO, CIB | Sale | 5,659 | Yes | 224,619 |
May 20, 2026 | Stacey Friedman | General Counsel | Sale | 5,468 | Yes | 46,428 |
Jun 22, 2026 | Stacey Friedman | General Counsel | Sale | 5,467 | Yes | 40,961 |
Note: All transactions are dispositions (sales) under pre-established 10b5-1 trading plans. No open-market purchases recorded in the period. The April 15 cluster of sales across the C-suite is consistent with post-earnings window opening and scheduled plan execution. Dimon’s 130,488-share sale is the largest by volume but represents a small fraction of his 1.68M+ share position. Source: SEC Form 4 Filings.